Intravenous Sotalol Loading for Cardiac Surgery AF Prevention

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Cardiothoracic surgery patients with a history of atrial fibrillation or atrial flutter face a high risk of developing these conditions during or after surgery, leading to prolonged hospital stays and increased mortality, and current oral sotalol administration requires a 3-day preoperative hospitalization due to the need for monitoring QT interval changes.

Innovation Solution

Intravenous loading and maintenance of sotalol hydrochloride in cardiothoracic surgery patients to reduce the risk of atrial fibrillation and atrial flutter, with a protocol involving targeted IV doses based on oral sotalol dosages, administered over specific time frames and monitored for QTc interval changes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If oral sotalol is administered to reduce postoperative AF risk, then the incidence of AF decreases, but preoperative hospitalization time increases to 3 days for monitoring

Engineering Contradiction:
ImproveAF prevention effectivenessVSAvoidpreoperative hospitalization time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the administration parameter from oral to intravenous, which fundamentally alters the pharmacokinetic profile and allows for immediate therapeutic effect without the 3-day preoperative hospitalization required for oral sotalol loading

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent replaces the oral administration mechanism with intravenous administration, eliminating the need for extended preoperative monitoring and hospitalization while maintaining AF prevention effectiveness

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Loss of time

If intravenous sotalol is administered to reduce AF risk without preoperative hospitalization, then hospital stay is shortened, but QT interval monitoring is required to ensure safety

Engineering Contradiction:
Improvehospital stay lengthVSAvoidmonitoring requirements
Core Design Contradiction:
Loss of timeVSDevice complexity

Solution Approach 1:

The patent implements continuous QT interval monitoring as a feedback mechanism during intravenous sotalol administration, allowing real-time adjustment of dosing to prevent arrhythmias while enabling shorter hospital stays compared to oral administration protocols

Inventive Principle:
Principle #23Feedback

Data Source

PatentUS20210283049A1Intravenous sotalol hydrochloride loading and maintenance for cardiac surgery patients
Publication Date: 2021.09.16 ALTATHERA PHARMACEUTICALS LLC

AI summary

The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol loading and maintenance for cardiothoracic surgery patients.